Statins and clinical outcomes in heart failure

Clinical Science

Volumn 113, Issue 3-4, 2007, Pages 119-127

  Martin, Jennifer H ^a   Krum, Henry ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

3 Hydroxy 3 methylglutaryl CoA reductase (HMG CoA reductase); Clinical trial; Heart failure; Infarction; Mortality; Remodelling; Statin

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERIVASTATIN; CHOLESTEROL; CYTOKINE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UBIQUINONE; VALSARTAN; CARDIOVASCULAR AGENT;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG MECHANISM; HEART FAILURE; HEART INFARCTION; HUMAN; LOW DRUG DOSE; MYOPATHY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; BLOOD; CONGESTIVE HEART FAILURE; DRUG EFFECT; HEART VENTRICLE REMODELING; PATHOPHYSIOLOGY;

CARDIOVASCULAR AGENTS; CHOLESTEROL; CYTOKINES; HEART FAILURE, CONGESTIVE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 34547612658     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20070031     Document Type: Review

References (88)

1. Scandinavian Simvastatin Survival Study Investigators (1994) Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389
2. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22
3. Aronow, H., Topol, E. J., Roe, M. T. et al. (2001) Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 357, 1063-1068
4. Stenestrand, U. and Wallentin, L. (2001) Early statin treatment following acute myocardial infarction and 1-year survival. JAMA, J. Am. Med. Assoc. 285, 430-436
5. Ferrieres, J., Cambou, J., Cantet, C. and Guize, L. (2006) Prognosis at 6 months for coronary and cerebrovascular patients: impact of antiplatelet agents and statins: results from the Prevenir III study. Cardiovasc. Drugs Ther. 20, 55-61
6. Chan, A. W., Bhatt, D. L., Chew, D. P. et al. (2002) Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 105, 691-696
7. McGirt, M., Perler, B., Brooke, B. et al. (2005) 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy. J. Vasc. Surg. 42, 829-836
8. Yasuda, H., Yuen, P., Hu, X., Zhou, H. and Star, R. (2006) Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int. 69, 1535-1542
9. Tousoulis, D. (2007) Statins in heart failure: beyond the lipid lowering effect. Int. J. Cardiol. 115, 144-150
10. Udell, J. (2006) Primary and secondary prevention of heart failure with statins. Expert Rev. Cardiovasc. Ther. 4, 917-926
11. Khush, K. (2006) Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials. J. Card. Failure 12, 664-674
12. van de Harst, P., Voors, A. A., van Gilst, W. H., Bohm, M. and van Veldhuisen, D. J. (2006) Statins in the treatment of chronic heart failure: a systematic review. PLoS Med. 3, e333
13. Kurian, K. (2006) The effect of statins in heart failure: beyond its cholesterol-lowering effect. J. Card. Failure 12, 473-478
14. Rauchhaus, M., Coats, A. J. and Anker, S. D. (2000) The endotoxin-lipoprotein hypothesis. Lancet 356, 930-933
15. Kronmal, R. (1993) Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch. Intern. Med. 153, 1065-1073
16. Krum, H., Tonkin, A., Currie, R., Djundjek, R. and Johnston, C. (2001) Chronic heart failure in Australian general practice. The Cardiac Awareness Survey and Evaluation (CASE) Study. Med. J. Aust. 174, 439-444
17. Onder, G., Landi, F., Volpato, S. et al. (2003) Serum cholesterol levels and in-hospital mortality in the elderly. Am. J. Med. 115, 265-271
18. Rauchhaus, M., Clark, A., Doehner, W. et al. (2003) The relationship between cholesterol and survival in patients with chronic heart failure. J. Am. Coll. Cardiol. 42, 1933-1940
19. Rauchhaus, M., Koloczek, V., Hans-Dieter, V. et al. (2000) Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int. J. Cardiol. 76, 125-133
20. Go, A., Lee, W., Yang, J., Lo, J. and Gurwitz, J. (2006) Statin therapy and risks of death and hospitalization in chronic heart failure. JAMA, J. Am. Med. Assoc. 296, 2105-2111
21. Martin, J. and Krum, H. (2003) Cytochrome P450 drug interactions within the HMG-CoA reducatse inhibitor class: are they clinically relevant? Drug Saf. 26, 13-21
22. 21a Erratum. Drug Saf. 26, 893
23. Moosmann, B. and Behl, C. (2004) Selenoproteins, cholesterol-lowering drugs, and the consequences: revisiting of the mevalonate pathway. Trends Cardiovasc. Med. 14, 273-281
24. Cohn, J. N., Johnson, G. C. and Shabetai, R. (1993) Mechanistic data from the VA Cooperative studies: ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 86, VI5-VI16
25. Floras, J. (1993) Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J. Am. Coll. Cardiol. 4, 72A-84A
26. Pliquett, R., Cornish, K. and Zucker, I. (2001) Statins: the effects on sympathetic nerve activity in heart failure. J. Card. Failure 7, 16
27. Pliquett, R. U., Cornish, K. G., Peuler, J. D. and Zucker, I. H. (2003) Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 107, 2493-2498
28. Pehlivanidis, A., Athyros, V., Demitriadis, D. et al. (2001) Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 151, 463-469
29. Bauersachs, J., Galuppo, P., Fracarollo, D. et al. (2001) Improvement of left ventricular remodelling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104, 982-987
30. Martin, J., Denver, R., Bailey, M. and Krum, H. (2005) In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling. Clin. Exp. Pharmacol. Physiol. 32, 697-701
31. Grip, O., Janciauskiene, S. and Lindgren, S. (2000) Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. Eur. J. Pharmacol. 410, 83-92
32. Holm, T., Andreassen, A. K., Ueland, T. et al. (2001) Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am. J. Cardiol. 87, 815-818
33. Park, J. K., Muller, D. N., Mervaala, E. M. et al. (2000) Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int. 58, 1420-1430
34. Oi, S., Haneda, T., Osaki, J. et al. (1999) Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur. J. Pharmacol. 376, 139-148
35. Takemoto, M., Grimm, M., Takemoto, Y. et al. (2000) HMG-CoA reductase inhibitors attenuate angiotensin-II induced cardiac hypertrophy. Circulation 102 (Suppl. II), II-133
36. Hasegawa, H., Yamamoto, R., Takano, H. et al. (2003) 3-Hydroxy-3- methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J. Mol. Cell. Cardiol. 35, 953-960
37. Kang, P. and Izumo, S. (2000) Apoptosis and heart failure: a critical review of the literature. Circ. Res. 86, 1107-1113
38. Kureishi, Y., Luo, Z., Shoijima, I. et al. (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6, 1004-1010
39. Vaughan, C., Murphy, M. B. and Buckley, B. M. (1996) Stalins do more than just lower cholesterol. Lancet 348, 1079-1082
40. Laufs, U., La Fata, V., Plutzky, J. and Liao, J. (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97, 1129-1135
41. Feron, O., Dessy, C., Desager, J. and Balligand, J. (2001) Hydroxy-methylglutarylcoenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 103, 113-118
42. Vergnani, L., Hatrik, S., Ricci, F., Passaro, A., Manzoli, N. and Zuliani, G. (2000) Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: key role of 1 arginine availability. Circulation 101, 1261-1266
43. Nahrendorf, M., Hu, K., Hiller, K.-H. et al. (2002) Impact of hydroxymethylglutaryl conenzyme A reductase inhibition on left ventricular remodeling after myocardial infarction. J. Am. Coll. Cardiol. 40, 1695-1700
44. Yokota, T., Utsunomiya, K., Murakawa, Y., Kurata, H. and Tajima, N. (1999) Mechanism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy. Kidney Int. (Suppl.) 71, S178-S181
45. Vrtovsnik, F., Couette, S., Prie, D., Lallemand, D. and Friedlander, G. (1997) Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway. Kidney Int. 52, 1016-1027
46. Negre-Aminou, P., van Vliet, A. K., van Erck, M., van Thiel, G. C., van Leeuwen, R. E. and Cohen, L. H. (1997) Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim. Biophys. Acta 1345, 259-268
47. Koch, G., Benz, C., Schmidt, G. et al. (1997) Role of Rho proteins in lovastatin-induced breakdown of actin cytoskeleton. J. Pharmacol. Exp. Then 283, 901-909
48. Reissen, R., Axel, D., Fenchel, M., Herzog, U., Rossmann, H. and Karsch, K. (1999) Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells. Basic Res. Cardiol. 94, 322-332
49. Spinale, F. G., Coker, M. L., Bond, B. R. and Zellner, J. L. (2000) Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc. Res. 46, 225-238
50. Indolfi, C., Di Lorenzo, E., Perrino, C. et al. (2002) Hydroxymethylglutaryl coenzyme a reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation 106, 2118-2124
51. Hayashidani, S., Tsutsui, H., Shiomi, T. et al. (2002) Fluvastatin, a 3-hydroxy-3-methylglutaryl Coenzyme A reductase inhibitor attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105, 868-873
52. Chen, M., Lam, A., Abraham, J. et al. (2000) CTGF expression is induced by TGF-β in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J. Mol. Cell. Cardiol. 32, 1805-1819
53. Ruperez, M., Lorenzo, O., Blanco-Colio, L., Esteban, V., Egido, J. and Ruiz-Ortega, M. (2003) Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation 108, 1499-1505
54. Martin, J., Connelly, K., Boyle, A. et al. (2006) Hyperglycemia has a detrimental effect on cardiac remodelling and mortality after myocardial infarction: benefit of statin therapy. Eur. Heart J. 27 (Suppl. 1), 522-523
55. Baeuerle, P., Rupec, R. and Pahl, H. (1996) Reactive oxygen intermediates as second messengers of a general pathogen response. Pathol. Biol. (Paris) 44, 29-35
56. Okazaki, R., Matusuoka, K., Horiuchi, A., Maruyama, K. and Okazaki, I. (1998) Assays of serum laminin and type III procollagen peptide for monitoring the clinical course of diabetic microangiopathy. Diabetes Res. Clin. Pract. 5, 163-170
57. Ortego, M., Bustos, C., Hernandez-Presa, M. A. et al. (1999) Atorvastatin reduces NF-κ B activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 147, 253-261
58. Ridker, P. M. (1999) Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann. Intern. Med. 130, 933-937
59. Krum, H., Ashton, E., Reid, C. et al. (2007) Double-blind, randomized placebo-controlled, parallel-group, multi center, phase III study to assess the impact of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J. Card. Failure 13, 1-7
60. Bleske, B., Nicklas, J., Bard, R. et al. (2006) Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischaemic cardiomyopathy and average low density lipoprotein level. J. Am. Coll. Cardiol. 47, 338-341
61. Node, K., Fujita, M., Kitakaze, M. et al. (2003) Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108, 839-843
62. Laufs, U., Wassmann, S., Schackmann, S., Heeschen, C., Bohm, M. and Nickenig, G. (2004) Beneficial effects of statins in patients with non-ischemic heart failure. Z. Kardiol. 93, 103-108
63. Sola, S., Mir, M., Lerakis, S., Tandon, N. and Khan, B. (2006) Atorvastatin improves left ventricular systolic function and serum markers of inflammation in non-ischaemic heart failure. J. Am. Coll. Cardiol. 47, 332-337
64. Kjekshus, J., Pedersen, T., Olsson, A., Faergeman, O. and Pyorala, K. (1997) The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J. Card. Failure 3, 249-254
65. Aronow, W. and Ahn, C. (2002) Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > 125 mg/dl treated with statins versus no lipid lowering drug. Am. J. Cardiol. 90, 147-149
66. de Lorgeril, M., Salen, P., Bontemps, L., Belichard, P., Geyssant, A. and Itti, R. (1999) Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyshpidemic coronary patients. J. Cardiovasc. Pharmacol. 33, 473-478
67. Horwich, T., MacLellan, W. and Fonarow, G. (2004) Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J. Am. Coll. Cardiol. 43, 642-648
68. Hognestad, A., Dickstein, K., Myhre, E., Snappin, S. and Kjekshus, J. (2004) Effect of combined statin and β-blocker treatment on one-year morbidity and mortality after myocardial infarction associated with heart failure. Am. J. Cardiol. 93, 603-606
69. Sola, S., Mir, M., Rajagopalan, S., Helmy, T., Tandon, N. and Khan, B. (2005) Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J. Card. Failure 11, 607-612
70. Ray, J., Gong, Y., Sykora, K. and Tu, J. (2005) Statin use and survival outcomes in elderly patients with heart failure. Arch. Intern. Med. 165, 62-67
71. Foody, J., Shah, R., Galusha, D., Masoudi, F., Havranek, E. and Krumholz, H. (2006) Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113, 1086-1092
72. Folkeringa, R., Van Kraaij, D., Tieleman, R., Nieman, F., Pinto, Y. and Crijns, H. (2006) Statins associated with reduced mortality in patients admitted for congestive heart failure. J. Card. Failure 12, 134-138
73. Krum, H., Latini, R., Maggioni, A. et al. (2006) Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int. J. Cardiol., doi:10.1016/j.ijcard.2006.07.106
74. Krum, H., Bailey, M., Meyer, W. et al. (2006) Impact of statin therapy on clinical outcomes in chronic heart failure patients according to β-blocker use: results of CIBIS II. Cardiology 8, 28-34
75. Segal, R., Pitt, B., Poole-Wilson, P. A. et al. (2000) Effects of HMG-CoA reductase inhibitors (statins) in patients with heart failure. Eur. J. Heart Failure 2, (Suppl. 2), 96
76. Khush, K., Waters, D., Bittner, V. et al. (2007) Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 115, 576-583
77. Fukuta, H., Sane, D., Brucks, S. and Little, W. (2005) Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 112, 357-363
78. Emberson, J., Ng, L., Armitage, J., Bowman, L., Parish, S. and Collins, R. (2007) N-Terminal pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J. Am. Coll. Cardiol. 49, 311-319
79. Mozaffarian, D., Nye, R. and Levy, W. (2004) Statin therapy is associated with lower mortality among patients with severe heart failure. Am. J. Cardiol. 93, 1124-1129.
80. Joynt, K., Gattis, W., Hasselblad, V. et al. (2004) Effect of angiotensin-converting enzyme inhibitors, β blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. Am. J. Cardiol. 93, 783-785
81. Stumpf, C., Lehner, C., Yilmaz, A., Daniel, W. and Garlichs, C. (2003) Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. Clin. Sci. 105, 45-50
82. Rosolova, H., Cech, J., Simon, J. et al. (2005) Short to long term mortality of patients hospitalised with heart failure in the Czech Republic: a report from the EuroHeart Failure Survey. Eur. J. Heart Failure 7, 780-783
83. Ezekowitz, J., McAlister, F. and Humphries, K. et al. (2004) The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J. Am. Coll. Cardiol. 44, 1587-1592
84. Tousoulis, D., Antoniades, C., Bosinakou, E. et al. (2005) Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 91, 27-31
85. Hong, Y. J, Jeong, M. H., Hyun, D. W. et al. (2005) Prognostic significance of simvastatin therapy in patients with ischemic heart failure who underwent percutaneous coronary intervention for acute myocardial infarction. Am. J. Cardiol. 95, 619-622
86. Landmesser, U., Bahlmann, F., Mueller, M. et al. (2005) Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111, 2356-2363
87. Strey, C., Young, J., Molyneux, S. et al. (2005) Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis 179, 201-206
88. Sacks, F., Pfeffer, M., Moye, L. et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335, 1001-1009